BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.

AI/ML

Biotechnology

Pharmaceutical

Therapeutics

BigHat Bio

Mark DePristo

Randy Schreckhise

Vi Vu

Abiy Seifu

John Corbin

Mitchell Stieg

Leslie Grab

Danielle Landrein

Timothy Park

Charbel Eid

Eddie Abrams

Liz Schwarzbach

Peyton Greenside

The Advisory Team at BigHat Bio leverages their extensive expertise in biotechnology, pharmaceuticals, and AI to provide strategic guidance and insights. They play a crucial role in shaping the company's direction, ensuring the integration of cutting-edge science and technology to advance the development of safer, next-generation antibody therapeutics for challenging diseases.

Advisory Team

Research Team

Software Development Team

Advisory Team

About

Team members

Other teams at BigHat Bio

Research Team

Software Development Team